Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: Role of αvβ3 imaging in determining optimal window-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: Role of αvβ3 imaging in determining optimal window

Published:2015-12 Issue:12 Volume:42 Page:923-930
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Becker Stéphanie,Bohn Pierre,Bouyeure-Petit Anne-Charlotte,Modzelewski Romain,Gensanne David,Picquenot Jean-Michel,Dubray Bernard,Vera Pierre

Funder

Ligue Contre le Cancer de Haute Normandie

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference25 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer;Sandler;N Engl J Med,2006

3. FOLFIRI bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials;Petrelli;Clin Colorectal Cancer,2013

4. Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy;Ou;Int J Radiat Oncol Biol Phys,2009

5. Irradiation and bevacizumab in high-grade glioma retreatment settings;Niyazi;Int J Radiat Oncol Biol Phys,2012

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct antitumor activity of bevacizumab: an overlooked mechanism?;Frontiers in Pharmacology;2024-04-23

2. PET imaging of tumor vascular normalization in hepatocellular carcinoma;European Journal of Nuclear Medicine and Molecular Imaging;2023-07-17

3. Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?;Clinical Medicine Insights: Oncology;2022-01

4. Simulations on the efficacy of radiotherapy with different time schemes of antiangiogenic therapy;2021-09-06

5. Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma;Frontiers in Cell and Developmental Biology;2021-04-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3